North Carolina company owner pleads guilty over attempted technology sale to China
RALEIGH, N.C. (AP) — The owner of a North Carolina company pleaded guilty in federal court on Friday to trying to sell electronic devices that have military applications to China without having a required U.S. government license, authorities said.
David C. Bohmerwald, who was formally charged in October with violating the Export Control Reform Act and other portions of the federal code, entered the plea to a count before U.S. District Judge Terrence Boyle in Raleigh. Bohmerwald, 63, has a tentative sentencing date for mid-May, court records show. He could face up to 20 years in prison, according to a U.S. Justice Department news release.
Bohmerwald, the owner of Raleigh-based Components Cooper Inc., purchased 100 accelerometers from a U.S.-based electronic company, and then attempted to export the devices to a company in China, the release said, citing court documents and information presented in court.
An accelerometer, which measures the vibration, tilt and acceleration of a structure, can be used in aerospace and military applications, such as helping missiles fly more accurately and measuring the precise effect of munitions.
The electronics company notified law enforcement about Bohmerwald's purchase request. After receiving the accelerometers, Bohmerwald dropped off two parcels — one addressed to a business in China — at a shipping store, the release said. A federal agent held the package and found the 100 accelerometers inside.
Bohmerwald falsely listed the value of the package's content at $100, when the true value was nearly $20,000, according to the government, and he admitted to agents that he acquired the technology on behalf of a Chinese-based company while knowing about the export restrictions.
'The disruption of this scheme to illegally export sensitive technology means that accelerometers and other items will not be used by unauthorized individuals or for adversarial purposes,' said Cardell Morant, a special agent in charge who supervises Homeland Security Investigations, within the Department of Homeland Security, in the Carolinas.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
30 minutes ago
- Business Wire
CEA Opens Shanghai–Auckland–Buenos Aires "New International Land-Sea Trade Corridor" to First Bridge China and South America
SHANGHAI--(BUSINESS WIRE)--On June 18, 2025, China Eastern Airlines (CEA) and Auckland Airport signed a cooperation agreement in Shanghai. According to the plan, CEA will launch commercial flights in December 2025 from Shanghai Pudong International Airport to Ministro Pistarini International Airport via Auckland Airport. The signing ceremony was attended by government officials, corporate representatives, and heads from relevant departments. New Zealand's Prime Minister Christopher Luxon highlighted that the new route will enhance global connectivity by linking Auckland with the dynamic economies of Asia and South America. He also announced that New Zealand will implement a visa-free transit policy for Chinese travelers passing through Auckland. Since the opening of the route to Auckland in 2014, CEA has shown strong growth. Chairman Wang Zhiqing stated that the airline will leverage its Shanghai hub to accelerate the construction of its global route network. The new route will serve as a vital bridge among New Zealand, China, the Asia-Pacific region, and South America, supporting the Belt and Road Initiative. Auckland Airport expressed satisfaction with the imminent realization of the jointly envisioned " New International Land-Sea Trade Corridor". CEA, Auckland Airport's key partner and now the leading carrier on the China–New Zealand route, has maintained steady operations and consistently expanded capacity. The new service, to be operated twice weekly by Boeing 777, will be the only direct air link between Argentina and China, filling the gap in direct air services between the two nations. The "New International Land-Sea Trade Corridor" shortens travel time by 4–5 hours versus European or North American routes and offers direct flights, while also reducing jet lag—passengers only face a 4-hour time difference when transiting through Auckland, as opposed to 12 hours via traditional Western routes. CEA plans to apply for fifth freedom for this route, enabling passenger and cargo transport in Auckland, boosting economic, trade, and people-to-people exchanges among New Zealand, China, and Argentina. Currently, CEA operates flights from Auckland to both Shanghai Pudong and Hangzhou Xiaoshan. Following the new route launch, CEA will boost New Zealand–China capacity deployment, increasing Auckland–Shanghai flights from 7 to 9 weekly. Note: The new route remains subject to final regulatory approval.
San Francisco Chronicle
an hour ago
- San Francisco Chronicle
Russian attacks on Ukraine kill at least 5 and injure over a dozen
KYIV, Ukraine (AP) — A Russian drone and missile attack on Ukraine's capital overnight killed at least four people and injured others, according to Ukraine's emergency services, as rescue workers and firefighters sought to remove people they believed trapped under debris in a partially collapsed apartment building. The strikes came nearly a week after a combined Russian attack on Ukraine last Tuesday killed 28 people in Kyiv, 23 of them in a residential building that collapsed after sustaining a direct hit by a missile. Ukrainian President Volodymyr Zelenskyy called that attack one of the biggest bombardments of the war, now in its fourth year. In the early hours of Monday, drones and missiles hit residential areas, hospitals and sports infrastructure in numerous districts across Kyiv, emergency services said, with the most severe damage occurring in the Shevchenkivskyi district, where one section of a five-story apartment building collapsed. Four people were confirmed dead in the attack on the building while 10 others had been rescued, emergency services said, adding they believed others were still trapped beneath the debris. Another person was killed and eight injured in the city of Bila Tserkva in the Kyiv region, around 85 kilometers (53 miles) southwest of the capital.
Yahoo
an hour ago
- Yahoo
Idorsia's QUVIVIQ expands into China as Simcere receives NDA approval – Idorsia and Simcere update their licensing agreement
Ad hoc announcement pursuant to Art. 53 LR Idorsia to receive USD 50 million (an additional USD 30 million) approval milestone payment in return for a reduction in Simcere potential sales milestones and tiered royalty payments. Allschwil, Switzerland – June 23, 2025Idorsia Ltd. (SIX: IDIA) today announced that Simcere Pharmaceuticals Group Ltd ( 'Simcere') has received approval for QUVIVIQ® (daridorexant) from the Chinese National Medical Products Administration for the treatment of adult patients with insomnia characterized by difficulty falling asleep and/or maintaining sleep, with no psychotropic drug control labeling. In addition, Idorsia has reached an agreement with Simcere to update the terms of the licensing agreement for QUVIVIQ in China. André C. Muller, Chief Executive Officer of Idorsia, commented:'I want to congratulate everyone at Simcere and the team that supported them from Idorsia. Together they have been able to take our drug from pre-IND, through to local Phase 1 and Phase 3, and then filing, resulting in this approval at an incredible pace of 2.5 years since the signing of the license agreement. I'm very happy as QUVIVIQ becomes a truly global brand, now available to millions of patients in North America, Europe, Japan and China, and we aim to continue this expansion to new territories.' Ren Jinsheng, Chairman and Chief Executive Officer of Simcere, commented:'I echo the congratulations to both teams that have worked diligently together to get this approval. Importantly, the clinical results achieved in both the global and local trials have enabled QUVIVIQ to be approved with no psychotropic drug control labeling in China. We are committed to make QUVIVIQ available to a great number of patients suffering with chronic insomnia.' Under the updated terms of the agreement, Idorsia will receive an approval milestone payment of USD 50 million, commercial milestone payments of up to USD 93 million, and low- to high-single-digit tiered royalties on future net sales. Arno Groenewoud, Chief Financial Officer of Idorsia, commented:'The updated agreement with Simcere allows both companies to streamline the collaboration. The increased milestone payment of USD 50 million in 2025 underscores Simcere's commitment and confidence in the potential of QUVIVIQ, following its significant investment in sealing this approval for Chinese patients and the corresponding launch preparations.' In 2022, Idorsia and Simcere entered into an exclusive licensing agreement for Idorsia's QUVIVIQ in China. Under the agreement, Simcere has an exclusive right to develop and commercialize QUVIVIQ in the Greater China region (Mainland China, Hong Kong, and Macau). Notes to the editor About IdorsiaIdorsia Ltd is reaching out for more – we have more passion for science, we see more opportunities, and we want to help more patients. The purpose of Idorsia is to challenge accepted medical paradigms, answering the questions that matter most. To achieve this, we will discover, develop, and commercialize transformative medicines – either with in-house capabilities or together with partners – and evolve Idorsia into a leading biopharmaceutical company, with a strong scientific core. Headquartered near Basel, Switzerland – a European biotech hub – Idorsia has a highly experienced team of dedicated professionals, covering all disciplines from bench to bedside; QUVIVIQ™ (daridorexant), a different kind of insomnia treatment with the potential to revolutionize this mounting public health concern; strong partners to maximize the value of our portfolio; a promising in-house development pipeline; and a specialized drug discovery engine focused on small-molecule drugs that can change the treatment paradigm for many patients. Idorsia is listed on the SIX Swiss Exchange (ticker symbol: IDIA). For further information, please contactInvestor & Media RelationsIdorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil+41 58 844 10 – – The above information contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company's investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Attachment Press Release PDFSign in to access your portfolio
